CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

 

 

VENTRICULAR SEPTAL DEFECTS (VSD)

The Burden of Disease1-3

Symptoms of VSD Corresponding to Defect Size

Defect size as noted below is presented as a percentage of the aortic annulus diameter.

A small VSD of ≤ 25%


 

A moderate VSD of > 25% but < 75%


 

A large VSD of ≥ 75%. Infants with a large VSD have symptoms including


 


 


 

Other Symptoms in Adults

The severity of VSD symptoms often depends on the defect size. While smaller VSDs may not cause symptoms, moderate-to-large VSDs can allow for an increased volume of blood to pass through the defect, thereby increasing the workload on the heart.1


 

The Risk of a Late Diagnosis and Undertreatment

If left untreated, VSD can lead to pulmonary hypertension and/or congestive heart failure.2 Additionally, with unrepaired VSD, there is also an increased risk of infective endocarditis.4


 

Are there any treatment options for VSD patients?

Medical therapy may be used to treat symptoms associated with muscular VSD but does not address the underlying pathology. Additionally, both transcatheter and surgical closure are options for patients with moderate-to-large VSDs.

Treatment for post-myocardial infarction (MI) muscular VSD is critical.5 However, medical therapy may be insufficient and surgical closure may not be an option for high risk patients.1,6,7

A post-myocardial infarction muscular VSD is a life-threatening complication that often leads to cardiogenic shock.5 Medical treatment alone is associated with a poor prognosis of a 94% mortality rate at 30 days.6

The Amplatzer™ Ventricular Septal Defect Occluder Solutions

Abbott offers two transcatheter devices for VSD closure, the Amplatzer™ Muscular VSD Occluder and the Amplatzer™ P.I. Muscular VSD Occluder. Providing a solution for:7,8

 

 

References

References: 

1.  Dakkak, W., Oliver, TI., (2019). Ventricular Septal Defect. StatPearls Publishing 2020, https:// www.ncbi.nlm.nih.gov/pubmed/29261884 - Accessed September 2022.

2.  Taylor MD. Ventricular Septal Defect, Muscular Clinical Presentation. Medscape Reference. http://emedicine.medscape.com/article/899873-clinical. Accessed September 2022.

3.  Australian Institute of Health and Welfare 2019. Congenital heart disease in Australia. Cat. no. CDK 14. Canberra: AIHW.

4.  Stout, KK, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e698–e800.

5.  Schlotter F, et al. Interventional post-myocardial infarction ventricular septal defect closure: a systematic review of current evidence. EuroIntervention. 2016;12:94-102.

6.  Crenshaw BS, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101(1):27-32.

7.  Amplatzer™ Muscular VSD Occluder Instructions for Use.

8.  Amplatzer™ Post-infarct Muscular VSD Occluder Instructions for Use.

Why Choose the Amplatzer™ Ventricular Septal Defect (VSD) Occlusion Devices?

Abbott’s Amplatzer™ portfolio is a pioneer in the treatment of structural heart defects and has retained its leadership position in structural heart innovation and treatment worldwide.1


 

Treat Complex VSDs

Specifically designed to close complex VSDs in patients considered to be high risk for surgical repair.2-3

Engineered for Complete Closure

Occluder devices centre and fill the defect using materials that promote occlusion and tissue in-growth.2-3

Offers Procedural Flexibility

For femoral or arterial delivery. Devices are designed to be recapturable and redeployable for precise placement.

Discover the Amplatzer™ VSD Closure Range to Optimise Patient Care

Abbott offers two devices for transcatheter VSD closure:

The Amplatzer™ Muscular VSD Occluder designed for muscular VSD closure in patients considered to be high risk for standard surgical repair


 

The Amplatzer™ P.I. Muscular VSD Occluder designed for the damaged muscular tissue in the septal wall of patients who have had a myocardial infarction


 


 

References

References:

1.  Data on file at Abbott.

2.  Dakkak, W., Oliver, TI., (2019). Ventricular Septal Defect. StatPearls Publishing 2020, https://www.ncbi.nlm.nih.gov/pubmed/29261884 - Accessed September 2022.

3.  Amplatzer™ Muscular VSD Occluder Instructions for Use.

Clinical Evidence: Amplatzer™ Ventricular Septal Defect (VSD) Occluders

Amplatzer™ VSD Occluder demonstrated closure success in patients with VSD2

The Amplatzer™ VSD Occluder was evaluated in a prospective, non-randomised, multi-centre clinical study in 38 patients considered to be high risk for standard surgical repair of muscular VSD.2

Study Results Showed:2


 



*Patients who had a shunt ≤ 2 mm at follow-up interval as assessed by investigator.

Amplatzer™ P.I. Muscular VSD Occluder

The safety and effectiveness of the Amplatzer™ P.I. Muscular VSD Occluder were evaluated in 44 post-myocardial infarction VSD patients.3

Study Results Showed:3

 

*Patients in which device placement was attempted and a device was successfully deployed in a defect during a catheterisation at some point during the study.

†Successful closure of the defect was defined as ≤ 2-mm residual shunt, but may include shunts up to 2.9 mm. Rate is per patients seen.

‡Successful closure of the defect was defined as ≤ 2-mm residual shunt. Rate is per patients seen.

§Major adverse events were reported between Days 0 and 84. 1/3 of major adverse events occurred within 24 hours of implant (at Day 0). 

References

References:

1.  Data on file at Abbott.

2.  Amplatzer™ Muscular VSD Occluder Instructions for Use

3.  Amplatzer™ P.I. Muscular VSD Occluder Instructions for Use.


 

NEW VERSION AVAILABLE

Get the Amplatzer™ Portfolio App

The Amplatzer™ App helps physicians determine which Amplatzer™ Structural Intervention device to use by suggesting applicable devices based on respective Instructions for Use.

App Store
Google play


 


 

Abbott's Structural Heart Portfolio

Navigate to discover solutions for the following disease areas:

Back to top

 

MAT-2208189 v1.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise My Wellington, Auckland 1060 Tel: 0800 827 285

Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 9391

MAT-2105201 v6.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

MAT-2105201 v1.0